LIVN · LivaNova PLC
$80.90
-0.46% last session
End-of-day data · close of 2026-10-23
Market cap
$4B
Enterprise value
$4B
Trailing P/E
23.9
Forward P/E
17.3
Dividend yield
0.0%
Beta
0.88
Avg volume
1M
Employees
3K
Daily Change %
-0.46%
5 Days Change
4.76%
10 Days Change
6.42%
30 Days Change
5.33%
60 Days Change
3.85%
Month to Day Change
8.80%
Year to Day Change
32.08%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — LIVN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-07
Latest call per bank · past 12 months
Barclays
Overweight$105
+29.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | Barclays | Initiates | Overweight | $0.00 → $105 |
| 2026-09-02 | Piper Sandler | Reiterates | Overweight | $87.00 → $90.00 |
| 2026-08-05 | Needham | Maintains | Buy | $81.00 → $93.00 |
| 2026-07-15 | Mizuho | Maintains | Outperform | $90.00 → $95.00 |
| 2026-07-01 | Freedom Capital Markets | Initiates | Hold | $0.00 → $81.00 |
| 2026-06-22 | Keybanc | Maintains | Overweight | $83.00 → $92.00 |
| 2026-05-07 | Barclays | Maintains | Equal-Weight | $73.00 → $76.00 |
| 2026-05-07 | Mizuho | Maintains | Outperform | $85.00 → $90.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 60 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 3.0% above the 50-day MA ($78.51).
- bullish: Price vs 200-day MA: Trading 11.7% above the 200-day MA ($72.46).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.62) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($49.57) and high ($85.32).
LIVN Price Chart
Loading chart for LIVN…
Fundamentals
About LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.
More in Medical Devices
ABT
Abbott Laboratories
$179B -16.2% YTD
MDT
Medtronic plc.
$122B 3.1% YTD
SYK
Stryker Corporation
$118B -11.9% YTD
BSX
Boston Scientific Corporation
$66B -51.7% YTD
EW
Edwards Lifesciences Corporatio
$51B 5.7% YTD
GEHC
GE HealthCare Technologies Inc.
$33B -12.8% YTD
DXCM
DexCom, Inc.
$29B 18.0% YTD
PHG
Koninklijke Philips N.V. NY Reg
$26B 3.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.